‘Assassin’s Creed Valhalla’ update lets you turn off cinematic kill animations


Sana Biotechnology to Present Preclinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021

– Fusogen platform demonstrates potential for in vivo delivery of cell-specific gene therapies to multiple cell types including T cells and hepatocytes – SEATTLE, April 27, 2021 (GLOBE NEWSWIRE) – Sana Biotechnology, Inc (NASDAQ: SANA), a company focused on the creation and delivery of engineered cells as drugs, today announced data from its fusogen technology platform, which is being presented at the 2021 annual meeting of the ‘American Society of Gene & Cell Therapy (ASGCT). The data presented demonstrate in vivo gene delivery to T cells and hepatocytes using a re-targetable fusogen delivery method. Sana is developing fusogens as a platform technology to enable the delivery of genetic loads to specific cell types. Fusogens can bind to cell surface proteins on the target cell type and then deliver the genetic load directly to the cytoplasm of the cell. The reliable and efficient delivery of genetic payloads to specific cell types is considered a major obstacle to achieving safe and efficient genetic modification in vivo. “These early data are encouraging in showing that our fusogenic platform can not only target specific and varied cell types, but also demonstrate the destruction and eradication of tumor cells both in vitro and in vivo,” said Sunil Agarwal, Chief Development Officer and Medical Director of Sana. “The potential of fusogens to target and deliver therapies to CD4 T cells, CD8 T cells and hepatocytes in vivo highlights the scope of our technologies beyond a single cell type or disease. Although preliminary, the development of optimized fusogens represents an important step towards increasing gene therapy options for patients with various cancers and genetic diseases. Data on the fusogen platform was presented in the poster presentation summary and made available to the public online today. The full poster will be available to ASGCT conference attendees beginning Tuesday, May 11 at 6:00 a.m. Eastern Time. Gene delivery in vivo to T cells and hepatocytes obtained using a re-targetable fusogenic platform Authors: Jagesh Shah, PhD, et al. Key takeaways are as follows: For T cells, CD8-targeted fusogens have shown cell-specific selectivity and efficient gene transduction in vitro and in vivo, leading to dose-dependent eradication of tumors in vivo demonstrable. cell surface proteins and efficient transduction both in modified cell lines and in human hepatocytes. These experimental results demonstrate the potential of fusogen-targeted vectors to deliver genes efficiently and with cell specificity in vivo, opening pathways to future gene therapies for a diverse set of diseases. About Sana Biotechnology Sana Biotechnology, Inc. is focused on the creation and delivery of engineered cells as drugs for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies available to patients. We are over 280 people working together to create a sustainable business that is changing the way the world treats disease. Sana has operations in Seattle, Cambridge and South San Francisco. For more information on Sana Biotechnology, please visit https://sana.com/. Caution Regarding Forward-Looking Statements This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company”, “we”, “us” or “our”) within the meaning of federal securities laws, including those related to Sana’s mission and progress, the ability to deliver genetic loads in vivo to specific cell types reliably and efficiently, the ability to increase gene therapy options for patients, and posters at the ASGCT. All statements other than statements of historical fact contained in this press release, including, but not limited to, statements regarding the strategy, expectations, cash flow and future financial condition of the company, future operations and outlook, are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “aim”, “anticipate”, “assume”, “believe”, “consider”, “continue”, “could”, “conceive”, “deadline” , “” Estimate “,” expect “,” objective “,” intend “,” may “,” objective “,” plan “,” positioned “,” potential “,” predict “,” seek ” , “should”, “target,” will “,” would “and other similar expressions which are predictions or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements in large part on its current expectations, estimates, forecasts and projections regarding future events and financial trends that it believes could affect its financial condition, results of operations, and strategy. business and financial needs. In light of the material uncertainties in these forward-looking statements, you should not rely on forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause actual results to vary significantly, including, but not limited to, risks inherent in drug development such as those associated with initiation, cost, timing, progress and to the results of current and future society. research and development programs, preclinical and clinical trials. For a detailed analysis of the risk factors that could affect the actual results of the Company, please refer to the risk factors identified in the Company’s SEC reports, including, but not limited to, its annual report on Form 10-K dated March 24, 2021. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason. Investor Relations: Nicole [email protected] Media: Morgan Warners, Finsbury Glover [email protected]

Source link

Previous Howard Ruby's Italian villa in Bel-Air hits the market for $ 45 million
Next Revance to present clinical results at the 2021 Aesthetic Meeting which supports the 24-week long-lasting profile of DaxibotulinumtoxinA in several female age cohorts